Cardioprotective effects of the estrogen receptors modulators in the conditions of experimental acute myocardial infarction

S. V. Pavlov, K. V. Levchenko, S. V. Gorbachova
Zaporizhzhia State Medical University, Ukraine

According to modern ideas, in myocardial infarction a cascade of pathobiochemical reactions is triggered directly in the ischemic focus, leading to a disturbance in the metabolism of cardiomyocytes, the launch of “parasitral” energy-producing reactions, the development of mitochondrial dysfunction, the complete blockade of the macroergic compounds synthesis, and as a result, cells death. In this regard, in the acute period of myocardial infarction it is pathogenetically justified to use drugs that can affect cardiomyocytes metabolism and restore the course of bioenergetic reactions in the cell.

Aim of study – to evaluate the SERM cardioprotective effects in the conditions of acute myocardial infarction modelling with the use of the ST2 marker.

Materials and methods. The experimental part of the work was performed on 120 mature rats – males weighing 190–230 grams. Small-focal acute myocardial infarction was modelled by the administration of coronary artery spasm induced agents – pituitrin and β1, 2, 3 isoprenaline adrenomimetic for 3 days. The investigated drugs tamoxifen citrate (0.1 mg/kg) (reg. № EF3300), toremifene (0.1 mg/kg) (reg. № 1705834), and also comparators – thiostiazoline (50 mg/kg) (UA/2931/01/02) and capicor (6 mg/kg) (reg. № 11114) were injected intraperitoneally 20 minutes after the injection of isadrin for 3 days in the above stated doses. The myocardial infarction development was confirmed by electrocardiographic study, as well as the appearance of troponin I in blood plasma. The directivity and severity of pathobiochemical processes in the cardiac tissue, as well as the effect of the studied drugs on them, were studied through the enzyme-linked immunosorbent assay of nitrozone and homocysteine concentration in the heart homogenate and ST2 in blood plasma.

Results. Systematic administration of a coronary artery spasm induced agents to laboratory animals led to a gradual, progressive ischemic lesion of myocardium. Biological markers of myocardial infarction Troponin, ST2 I were registered on the 3rd day after the administration of pituitrin and isadrin in the blood plasma of the control group. Using selective receptors modulators and reference preparations (thiostiazoline, capicor) in experimental therapy of rats with experimental myocardial infarction promoted the normalization of biochemical processes in cardiomyocytes. However, the effect of the studied drugs was unidirectional with various degree of intensity. All the drugs statistically significantly reduced oxidative stress marker products. The most marked effects were displayed by the selective estrogen receptors modulators toremifene and tamoxifen, which decreased in ST2 blood plasma level (by more than 46 %) providing realization of IL-33 cardioprotective properties. In addition, SERM can limit oxidative and nitrosyl stresses development, leading to a decrease in the concentration of homocysteine and nitrozone in the heart. Interaction of these effects of tamoxifen citrate in conditions of acute myocardial infarction modelling resulted in a marked cardioprotective effect, increasing the percentage of animals which survived to an average of 75 %.

Conclusions. The cardioprotective effects of selective estrogen receptor modulators identified by us are an experimental foundation for the relevance and viability of further research in this direction.

Кардіопротективні ефекти модуляторів естрогенових рецепторів в умовах експериментального інфаркту міокарда

С. В. Павлов, К. В. Левченко, С. В. Горбачова

Відповідно до сучасних уявлень, при інфаркті міокарда більш попередньо в осередку ішемії запускається каскад патобіохімічних реакцій, що призводить до порушення метаболізму кардіоміоцитів, запуску «паразитарних» енергорозподілових реакцій, розвитку мітохондріальної дисфункції, повної блокади синтезу макроергів та, як наслідок, загибелі клітин.

Мета роботи – оцінювання кардіопротективних ефектів селективних модуляторів естрогенових рецепторів в умовах моделювання гострого інфаркту міокарда з використанням маркера ST2.

Матеріали та методи. Експериментальна частина роботи виконана на 120 статевозрілих щурів-самцях масою 190–230 г.

Результати. Систематичне введення лабораторним тваринам коронароспастичного агента призводило до поступового, прогресивного ішемічного ураження кардіоміоцитів, запуску “паразитарних” енергорозподілових реакцій, розвитку мітохондріальної дисфункції, повної блокади синтезу макроергів та, як наслідок, загибелі клітин.

Закінчення. Селективні модулятори естрогенових рецепторів здатні впливати на метаболізм кардіоміоцитів і відновлювати біоенергетичні реакції у клітині в гострий період інфаркту міокарда, а також розробка нових методів лабораторного скринінгу ефективності проведеної терапії.

Ключові слова: гіпоксія, кардіоміоцити, селективні модулятори рецепторів естрогенів, цитопротекція, ST2.

Кардиопротективні ефекти модуляторів естрогенових рецепторів в умовах експериментального острого інфаркту міокарда

С. В. Павлов, К. В. Левченко, С. В. Горбачова

Согласно современным представлениям, при инфаркте миокарда непосредственно в очаге ишемии запускается каскад патобиохимических реакций, приводящий к нарушению метаболизма кардиомиоцитов, запуску «параситарных» энергопродуцирующих реакций, развитию мitoхондриальной дисфункции, полной блокаде синтеза макроэргов и, как следствие, гибели клеток. В этой связи актуальным является поиск новых высокоэффективных лекарственных препаратов, способных воздействовать на метаболизм кардиомиоцитов и восстанавливать течение биоэнергетических реакций в клетке в острый период инфаркта миокарда, а также разработка новых методов лабораторного скрининга эффективности проводимой терапии.

Цель работы – оценка кардиопротективных эффектов селективных модуляторов эстрогеновых рецепторов в условиях моделирования острого инфаркта миокарда с использованием маркера ST2.

Материалы и методы. Экспериментальная часть работы выполнена на 120 половозрелых крысах-самцах массой 190–230 г. Мелкоочаговый острый инфаркт миокарда моделировали путем введения на протяжении 3 суток коронасоспазмирующего агента питаутрина и β1, 2, 3 адреномиметика изопrenalина. Исследуемые препараты: тамоксифен цитрат (0,1 мг/кг, рег. № EP3300), торемифен (0,1 мг/кг, рег. № 1705834), а также референс-препараты тиотриазолин (50 мг/кг, UA/2931/01/02) и капикор (6 мг/кг, рег. № 11114) вводили внутрибрюшинно через 20 минут после введения изадрина на протяжении 3 дней. Наличие инфаркта миокарда подтверждали электрокардиографическим исследованием, а также определением тропонина I в плазме крови. Направленность и выраженность патобиохимических процессов в сердечной ткани и влияние на них исследуемых препаратов изучали по иммуноферментному определению концентрации в гомогенате сердца нитротирозина, гомоцистеина (Homocysteine), в плазме крови – ST2.

Результаты. Систематическое введение лабораторным животным коронасоспазматического агента приводило к постепенному, прогрессирующему ишемическому поражению кардиомиоцитов. В плазме крови животных контрольной группы зарегистрировано увеличение биологического маркера инфаркта миокарда тропонина I, ST2. В гомогенате сердца зафиксировано развитие ожоговой дисфункции, а также снижение концентрации нитротирозина и гомоцистеина. Экспериментальная терапия селективными модуляторами эстрогеновых рецепторов и референс-препаратами (тиотриазолин, капикор) способствовала нормализации биохимических процессов в кардиомиоцитах. Действие исследуемых препаратов было однородным, однако различной степени выраженности. Все препараты статистически достоверно снижали маркерные продукты оксидативного стресса, а также концентрацию маркера ST2 в плазме. Наиболее выраженные эффекты продемонстрировали селективные модуляторы эстрогеновых рецепторов тамоксифен и торемифен, которые уменьшали содержание в плазме крови ST2 (более чем на 46 %), обеспечивая реализацию кардиопротективных свойств IL-33. Кроме того, SERM способны ограничивать развитие оксидативного и нитрозильного стресса, приводя к снижению концентрации в сердце гомоцистеина и нитротирозина. Взаимопотенцирование данных эффектов тамоксифена цитрата в условиях моделирования острого инфаркта миокарда приводило к выраженному кардиопротективному эффекту, увеличивая процент выживших животных в среднем до 75 %.

Выводы. Установленные нами кардиопротективные эффекты селективных модуляторов эстрогеновых рецепторов являются экспериментальным обоснованием актуальности и перспективности дальнейших исследований в этом направлении.

According to modern ideas, in myocardial infarction a cascade of pathobiochemical reactions is triggered directly in the ischemic focus, leading to a disturbance in the metabolism of cardiomyocytes, the launch of ‘parasitral’ energy-producing reactions, the development of mitochondrial dysfunction, the complete blockade of the macroergic compounds synthesis, and as a result, cells death. In this regard, in the acute period of myocardial infarction it is pathogenetically justified to use drugs that can affect cardiomyocytes metabolism and restore the course of bioenergetic reactions in the cell [1,2].

As of today, there are many metabolotrophic cardio-protectors, – antihypoxants, antioxidants, antianginal drugs among them. However, the effectiveness of these drugs is only proven in subacute and recovery periods of myocardial infarction, the drugs are used chaotically, without a treatment strategy from the position of evidence-based medicine. In addition, these drugs in mitochondrial dysfunction forming conditions are not able to regulate the good molecular-biochemical pathways of energy metabolism [1].

A promising trend of new cytoprotective drugs development used in hypoxic cells damage is searching for...
the compounds that could induce endogenous cytoprotective factors (HSP-protein; HIF-proteins, NO) [2–4]. It is known that these factors play a key role in the implementation of compensatory-adaptive reactions of cells and activation of endogenous mechanisms of cytoprotection in response to hypoxia: inhibition of ATP hydrolysis and increase of anaerobic ATP formation, minimization of energy consumption, NO-dependent and humoral dilation of coronary and peripheral vessels [5,6]. Experimental research of the past decade conducted in this area have found a number of factors that can induce expression of chaperones, beginning with preconditioning, heat-shock and magnetic field, and ending with some drugs (antioxidants, triterpene compounds, arimoclonol, adenosine, nitrates, valproic acid, estrogen, etc.) [6]. Among these, special attention should be paid to estrogens. Historically, the studies of estrogens were carried out concerning their impact on the secondary sexual characteristics in females, myometrium mitotic activity, ovarian follicular granulosa cell proliferation and others [7–9]. However, the detection of a large number of estrogen receptors in tissues that are not classical estrogen targets, both in female and male individuals, suggests that estrogens do not only regulate reproductive processes in the body [6,8,9]. The new concept of cardiac protective influence of estrogens based drugs, that has been mainly developed abroad, is based on a huge clinical material which indicates the ability of estrogens to prevent or slow down the progression of coronary heart disease, hypertension, paroxysmal forms of cardiac arrhythmias, atherosclerosis - especially in women with estrogens deficiency [6,9–11].

All of the above-mentioned provide foundation for the further study of estrogens cardioprotective properties. However, their direct hormonal activity and ambiguous effects on the blood clotting system limit estrogen cardioprotective drugs inclusion into treatment. In this regard, an interesting trend is the use of the so-called selective estrogen receptor modulators (SERM) as estrogen receptor agonists.

The unique pharmacology of SERM can be explained by three interacting mechanisms: 1) the differential expression of estrogen receptors in specific target tissue; 2) the differential conformation of the estrogen receptor upon binding ligand; 3) the differential expression and binding of co-regulatory protein with estrogen receptors [6,9]. The relative levels of two isoforms of estrogen receptors (ERα and ERβ) expression are believed to affect the cellular response to estrogens. SERM can function as full antagonists, acting through ERβ genes that contain relevant elements, but may play a role of partial agonists, acting through ERα [8,11].

Taking into account all the above-mentioned, it is important to study the SERM cytoprotective effects in the conditions of acute myocardial infarction modelling. In recent years, both experimental and clinical studies have shown that it is appropriate to use the detection of a cardiac biomarker ST2 (Growth Stimulation Expressed Gene 2) [12,13] for the purpose of new cardioprotective drugs effectiveness pharmacological evaluation. ST2 is a member of the interleukin-1 receptor family. In the heart, ST2 plays a biological role in the innate immune process, and also modulates the cardiac signalling pathway. An important feature of ST2 is the rapid, under ischemia, blockade of IL-33 cardioprotective effect, which contributes to the heart remodeling and fibrosis development [14]. With adequately selected cardioprotective therapy, the concentration of ST2 decreases rapidly, which explains the prospect of its use for cardioprotective properties of the drugs evaluation in the study [12–14].

Thus, the aim of our study was to evaluate the SERM cardioprotective effects in the conditions of acute myocardial infarction modelling with the use of the ST2 marker.

Materials and methods

The experimental part of the work was performed on 120 mature rats – males weighing 190–230 grams. Experimental animals were obtained from the Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine. Small-focal acute myocardial infarction was modelled by the introduction of coronary artery spasm induced agents – pituitrin (1 unit/kg subcutaneously) and β1, 2, 3 isoprenaline adrenomimetic (200 mg/kg intramuscularly) for 3 days [15]. The investigated drugs – tamoxifen citrate (0.1 mg/kg) (reg. № EF3300), toremifene (0.1 mg/kg) (reg. № 1705834), and also comparators – tiotiazoline (50 mg/kg) (UA/2931/01/02) and capicor (6 mg/kg) (reg. № 11114) were injected intraperitoneal 20 minutes after the injection of isadrin for 3 days in the above stated doses. The myocardial infarction development was confirmed by electrocardiographic study, as well as the appearance of troponin I by "Immulation troponin I Kit 100T" ("Siemens") in blood plasma. The directivity and severity of pathobiological processes in the cardiac tissue, as well as the effect of the studied drugs on them, were studied through the enzyme-linked immunosorosent assay of nitrotriogenine ("Nitrotrisein" (ELISA Kit "Hycult biotechnology bv")) and homocysteine ("Homocysteine" ("Axis-Shield Diagnostics")) concentration in the heart homogenerate and ST2 ("The Pressage ST2 Assay" (Critical Diagnostics)) in blood plasma.

The normality of the distribution was assessed by Kolmogorov–Smirnov (D), Lilliefors and Shapiro–Wilk (W) criteria. When the distribution was not normal or when we analyzed ordinal variables, we used the Mann–Whitney U test for two unrelated samples; for a larger number of samples, we used Kruskal–Wallis H test followed by the Games–Howell comparison. A comparison of groups on the basis of attributes was performed using χ² criterion with an analysis of contingency tables. Data are presented as the arithmetic mean and standard error of the representation of the mean value. The relationship between the studied variables was determined using binary regression analysis. The results were processed using the statistical software packages SPSS 16, Microsoft Excel 2003, and STATISTICA for Windows 7.0 (StatSoft Inc.); for all types of analysis a significance level of less than 0.05 was considered as a significant difference [16].

Results and discussion

Systematic administration of a coronary artery spasm induced agents to laboratory animals led to a gradual, progressive ischemic lesion of cardiomyocytes. As it can be seen in the Table 1, an increase in the biological marker of myocardial infarction, Troponin I, which concentration averaged 1.77 mg/ml, was registered on the 3rd day in the control group blood plasma after pituitrin and isadrin administration. Simultaneously, myocardial ischemia characterizing electrocardiographic changes were recorded
Table 1. The influence of the studied drugs on pathobiochemical changes in the blood plasma and homogenate of the rat heart with experimental myocardial infarction

<table>
<thead>
<tr>
<th>Groups of animals</th>
<th>Troponin I, mg/ml</th>
<th>ST2, mg/ml</th>
<th>Nitrotyrosine, Standard unit, /g/protein</th>
<th>Homocysteine, Mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact group (n = 10)</td>
<td>0.25 ± 0.02</td>
<td>11.4 ± 1.59</td>
<td>0.14 ± 0.03</td>
<td>0.4 ± 0.11</td>
</tr>
<tr>
<td>Control group (myocardial infarction)</td>
<td>1.77 ± 0.34*</td>
<td>47.2 ± 6.47*</td>
<td>1.3 ± 0.27*</td>
<td>3.7 ± 0.68*</td>
</tr>
</tbody>
</table>

*: p ≤ 0.05 in relation to the intact group of animals.

Fig. 1. Electrocardiogram of a rat with Q-myocardial infarction.

in these animals. Taking into account the peculiarities of the experimental model and the diffuse nature of ischemic myocardial damage, an increase in the ST segment from the isoinole and the amplitude of the T wave depression were revealed (Fig. 1).

An expected result of such changes was a statistically significant increase of the “soluble” ST2 receptor (sST2) in the plasma of the rats with experimental myocardial infarction. It is known that the receptor ST2 (suppression of tumorigenicity-2) is a representative of the interleukin IL-1 receptors family [12–14]. ST2 exists in two isoforms: transmembrane (ST2L) and “soluble” (sST2), which is not bound to the cell membrane and circulates freely in the circulatory system.

A number of studies have shown that interleukin-33 (IL-33) is the ligand of the ST2 receptor [12]. Hypoxic damage to cardiomyocytes and fibroblasts, excessive pressure and stretching are the main momentum of the IL-33/ST2 system activation in the heart [14]. IL-33 performs its cardioprotective effect in the interaction with the ST2L receptor [13–14]. At the same time, sST2 is a “trap” receptor, connecting with IL-33, is disconnected from the signal pathways and is unable to realize its cardioprotective effect [13]. In this regard, increasing the ST2 marker concentration is of practical importance in the diagnosis of cardiovascular diseases, as well as therapy effectiveness monitoring in both experimental and clinical studies.

As the studies showed, an increase in the ST2 concentration in the blood plasma of the rats with experimental myocardial infarction correlated with a statistically significant increase in markers of oxidative stress – nitrotyrosine (Ntz) and homocysteine (Gct) – in the stunned myocardium homogenate. The development of nitrosating stress (Ntz increasing by 91 %) on the background of the shift of thiol-disulphide equilibrium towards oxidized thiols (Gct increasing by 89 %). Under cardiomyocyte hypoxia, these pathobiochemical processes are able to cause a cascade of irreversible processes leading to the death of cardiomyocytes. Thus, the development of nitrative stress leads, through peroxynitrite hyperproduction, to the irreversible inhibition of mitochondrial respiration, directly interacting with the iron of key enzymes active centres, and also nitrosating the S-, N-, O-elements of thiol, phenol, hydroxyl and amino groups of the protein part of these enzymes; and in a stronger manifestation of nitrative stress, it irreversibly oxidizes them. In conditions of ischemic damage to heart tissue, the antioxidant balance shifts toward the prooxidant [17,18].

Accumulation of proteins oxidative degradation marker products occurs, especially Ntz, leading to the disruption in the functioning of proteins, especially the respiratory chain, and as a result, the death of the whole cell. Simultaneously, due to nucleic acids damage, oxidative stress leads to the inhibition of the genes expression responsible for the synthesis of endogenous cytoprotective factors (HSP-, HiF proteins), as well as antioxidant protection enzymes – catalase, superoxide dismutase [19].

Using tamoxifen (0.1 mg/kg), toremifene (0.1 mg/kg), thiotriazoline (50 mg/kg) and capicor (6 mg/kg) in experimental therapy of rats with experimental myocardial infarction promoted the normalization of biochemical processes in cardiomyocytes. Therefore, as it can be seen in the Table 2, all the studied drugs reduced the concentration of nitrotyrosin in the heart homogenate, with a parallel decrease in the content of homocysteine. However, the effect of the drugs in the study was unidirectional, with various degree of intensity. All the drugs statistically significantly reduced oxidative stress marker products. Selective estrogen receptor modulator toremifene and compound with antioxidant properties thiotriazoline, as it is shown in the Table 2, were found to be the most active in their effect on the oxidative stress indicators, as they reduced the concentration of nitrotyrosine and homocysteine by an average of 60 % and 70 %, respectively.

Interesting data were obtained by studying the character of ST2 concentration in the plasma of animals with myocardial infarction experimental therapy. So, it can be concluded from the Table 3, that the concentration of ST2 was comparable to the effectiveness of the drugs in their effect on the content of oxidative stress markers, although thiotriazoline showed slightly less activity. An important feature is that the obtained values of the ST2 concentration correspond with the number of survived animals in each experimental series. Therefore, the lower marker ST2 concentration, the larger number of experimental animals survived on the 4th day of the modelled pathology. Based on the ST2 concentration, it is possible to construct a series of the studied drugs in descending order of their efficiency. This series has the range: toremifene – tamoxifen – capicor – thiotriazoline.

The prospective use of ST2 as a marker for monitoring the drugs effectiveness is explained by the integrative properties of this biomarker, reflecting changes in the three main links of myocardial infarction: hypoxia, inflammation,
myocardial stress. As a “receptor-trap”, sST2 binds to IL-33 and limits the realization of its cardioprotective effect. A number of studies have shown the relationship between the development of oxidative stress and hyperproduction of sST2 [12–14]. In addition, due to the limitation of IL-33 biological effects, the cytoprotective activity of HSP and HIF proteins is also limited [5,20]. It is known that the induction of HSP and HIF proteins is the most conservative and universal system of cellular response to hypoxia. The ratio of the HSP level to the total protein level in a stress-affected cell is so large, that the amount of heat shock proteins in it reaches 15–20 % of all dissolved cytoplasm proteins [4,5,20]. The last one with these proteins expression and synthesis induction in a cell under hypoxic conditions a number of researchers associate with the initiation of adaptive molecular-biochemical cell reactions in response to hypoxia. In this regard, the established ability of drugs to reduce the concentration of ST2 allows us to make an assumption about their ability to influence the content of HSP proteins, thereby activating the processes of rapid cell adaptation to hypoxic conditions. This statement is especially true for estrogen receptors modulators - tamoxifen and toremifene, the mechanism of cytoprotective action of which in conditions of ischemic genesis pathology is explained, among other things, by their ability to increase the content of HSP and HIF proteins in the cell, as we have shown in our earlier research.

To sum up, it has been determined in the course of experimental research that the studied drugs in the conditions of experimental myocardial infarction have complex cytoprotective effects aimed at oxidative and nitrosative stresses reduction reducing the concentration of ST2 marker. The cytoprotective effects of the above-mentioned drugs established by us were manifested in the increased number of survived animals on the 4th day of myocardial infarction modelling. The analysis of the obtained data demonstrates that the leading mechanism of their cytoprotective effects is the ability to reduce the concentration of the ST2 marker. This property of the drugs is unidirectional, however it is realized in different ways. Thus, the antioxidant drug – tiotriazoline, is capable of binding the cytotoxic derivatives of the ROS to its SH-groups, thereby reducing the concentration of nitrotyrosine and homocysteine. Tiotriazoline showed less pronounced effects in relation to ST2 marker concentration, which prevented it from fully implementing cardioprotective effects. Under the influence of tiotriazoline, the percentage of survived animals on the 4th day of modelled pathology was only 50 %. Capicor proved to be more active, providing a decrease in ST2 by 33 %, and increasing the percentage of survived animals to 60 %. These effects of capicor, in our opinion, are explained by the combination of gamma-butyrobetaine dihydride with melardonium dihydride which, on the one hand, ensures the oxidative stress localization and on the other hand the normalization of biochemical processes in the mitochondria, reducing the lactic acidosis development. The most pronounced effects were displayed by the selective modulators of estrogen receptors – toremifene and tamoxifen. These drugs, in conditions of experimental myocardial infarction, due to the modulation of heart estrogen receptors (ER), caused conformational changes in the ER molecule and the release of HSP70 proteins from the complex with it and the input of the latter into the mitochondria. However, the decrease of ST2 in blood plasma (by more than 46 %) provides, in our opinion, the realization of IL-33 cardioprotective properties. In addition, SERM can limit the development of oxidative and nitrosative stresses, leading to a decrease in the concentration of homocysteine and nitrotyrosine in the heart. Interaction of these effects of tamoxifen citrate in conditions of acute cerebral ischemia led to a marked cardioprotective effect, increasing the percentage of survived animals to an average of 75 %.

Conclusions

1. Modelling of the acute myocardial infarction led to the significant pathobiological and electrophysiological changes in the heart tissue.

2. Experimental therapy of the rats with acute myocardial infarction with SERM and reference medications had cardioprotective effects, such as decrease of the oxidative and nitro-oxidative stresses markers, decrease of the serum ST2.

3. Effect of all medications in this study was unidirectional, but in the varying degrees. The most effective were Toremifen and Tamoxifen citriris, which decreased ST2 function more than 45 %, at the same time the percentage of survived animals was 45 %.

The cardioprotective effects of selective estrogen receptor modulators identified by us are an experimental foundation for the relevance and viability of further research in this direction.

Table 2. The effect of the studied drugs on the content of oxidative and nitrosative stresses markers in cardiac homogenate of rats with experimental myocardial infarction

<table>
<thead>
<tr>
<th>Groups of animals</th>
<th>Nitrotyrosine, Standard unit/g protein</th>
<th>Homocysteine, Mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact group, (n = 10)</td>
<td>0.14 ± 0.03</td>
<td>0.4 ± 0.11</td>
</tr>
<tr>
<td>Control group (myocardial infarction), (n = 10)</td>
<td>1.3 ± 0.27</td>
<td>3.7 ± 0.88</td>
</tr>
<tr>
<td>Myocardial infarction + Tamoxifene citrate (0.1 mg/kg), (n = 10)</td>
<td>0.65 ± 0.14*</td>
<td>2.7 ± 0.14*</td>
</tr>
<tr>
<td>Myocardial infarction + Toremifene (0.1 mg/kg), (n = 10)</td>
<td>0.52 ± 0.12*</td>
<td>1.1 ± 0.1*</td>
</tr>
<tr>
<td>Myocardial infarction + Tiotriazoline (50 mg/kg), (n = 10)</td>
<td>0.5 ± 0.09*</td>
<td>0.9 ± 0.08*</td>
</tr>
<tr>
<td>Myocardial infarction + capicor (6 mg/kg), (n = 10)</td>
<td>0.88 ± 0.11*</td>
<td>2.9 ± 0.12*</td>
</tr>
</tbody>
</table>

*: p ≤ 0.05 in relation to the control.

Table 3. The impact of the studied drugs on the content of ST2 in the blood plasma and the percentage of survived animals on the 4th day of experimental myocardial infarction

<table>
<thead>
<tr>
<th>Groups of animals</th>
<th>ST2, mg/ml</th>
<th>% of survived animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact group, (n = 10)</td>
<td>11.4 ± 1.59</td>
<td>0</td>
</tr>
<tr>
<td>Control group (myocardial infarction), (n = 10)</td>
<td>47.2 ± 6.47</td>
<td>40</td>
</tr>
<tr>
<td>Myocardial infarction + Tamoxifene citrate (0.1 mg/kg), (n = 10)</td>
<td>27.7 ± 4.2*</td>
<td>70</td>
</tr>
<tr>
<td>Myocardial infarction + Toremifene (0.1 mg/kg), (n = 10)</td>
<td>22.7 ± 3.72</td>
<td>80</td>
</tr>
<tr>
<td>Myocardial infarction + Tiotriazoline (50 mg/kg), (n = 10)</td>
<td>36.8 ± 4.12</td>
<td>50</td>
</tr>
<tr>
<td>Myocardial infarction + capicor (6 mg/kg), (n = 10)</td>
<td>32.2 ± 3.41</td>
<td>60</td>
</tr>
</tbody>
</table>

*: P ≤ 0.05 in relation to the control.

References


Оригінальні вивчення


